Interleukin-1 (IL-1) ()and tumor necrosis factor- (TNF-) are two important cytokines secreted primarily by activated macrophages and monocytes(1, 2, 3, 4, 5) . These cytokines elicit diverse biological effects ranging from those that are beneficial to the host, such as recruitment of immunological and anti-tumor responses, to those that may have deleterious consequences, such as cell proliferation and tissue injury, and inflammatory responses that may lead to toxic shock and sepsis(1, 2, 3, 4, 5) . In cell culture, these cytokines show pleiotrophic effects on the growth of mammalian cells. The growth regulatory effects of IL-1 and TNF- are cell type-dependent: the cytokines stimulate the growth of nontransformed cells such as fibroblasts (6, 7) and kidney epithelial cells (8) and transformed cells, such as glioblastoma (8, 9, 10) and renal carcinoma(11) , but inhibit the growth of certain nontransformed fibroblast cells(12) , and tumor cells, such as melanoma(8, 13) , breast carcinoma(14) , lung adenocarcinoma(15) , ovarian carcinoma (16) , and myeloid leukemia(17, 18) . Although these cytokines show overlapping biological activities, their action is mediated by distinct cell surface receptors(19, 20, 21) . Signal transduction and phenotypic alterations by IL-1 are mediated via IL-1-receptor type I(22, 23, 24) , whereas two different TNF- receptors mediate distinct phenotypic responses to TNF-(25) . The action of each of these cytokines is associated with diverse second messengers in the cytosol, which in turn activate DNA binding proteins, particularly AP-1 and NF-B, that lead to induction of a number of immediate-early and delayed response genes (cited in Refs. 24, 26, and 27). The mechanism of action of these cytokines is, however, not known.

To understand the molecular basis for the pleiotrophic effects of IL-1 on the growth of human cells, we are studying the gene programs associated with the actions of this cytokine(13) . Human melanoma cells, A375-C6, show growth arrest in response to IL-1 or TNF- and provide an excellent experimental model for exploring the molecular pathways that are initiated by the binding of these cytokines to the cognate cell surface receptors and that lead to a dose- and time-dependent growth arrest response(8, 13, 24) . The action of IL-1 and TNF- in the melanoma cells is dependent on induction of immediate-early genes(13) , which are expected to initiate a cascade of events leading to growth arrest. Fluorescence-assisted cell sorting (FACS) analysis has revealed that IL-1 causes growth arrest in the G/G phase of the cell cycle (24) .

Studies on cell cycle regulation have identified the product, RB, of the retinoblastoma susceptibility gene, Rb, as a key checkpoint control protein responsible for imposing a block in the cell cycle at the transition from the G to the S phase(28, 29) . Mutations that functionally inactivate the Rb gene have been identified in a variety of human tumors(30) . Moreover, ectopic expression of the wild-type Rb gene can suppress the growth of tumor cells in culture or the formation of tumors in animal models (31, 32) . The characterization of RB as a tumor suppressor has been further consolidated by the observations that three different transforming proteins encoded by DNA tumor viruses, adenovirus E1A, papovavirus large T antigen, and papillomavirus E7 protein, can bind to the RB protein at a domain called the A/B pocket and that the transforming functions of these proteins are linked to their ability to bind to RB protein(33, 34, 35, 36) . The RB protein is differentially phosphorylated during cell cycle progression(37, 38, 39, 40, 41) . It is unphosphorylated (RB) during the early and mid G phase, then phosphorylated by cyclin/cyclin-dependent kinase complexes during late G and further in the S phase. Late in mitosis, it is enzymatically dephosphorylated, and cells entering the next G phase contain primarily RB. These observations coupled with the facts that the large T antigen preferentially binds to RB and induces G-arrested cells to enter the S phase(42) , suggest that RB causes G phase growth arrest and RB phosphorylation is linked to rescue from such an arrest.

The A/B pocket domain of RB can bind and inhibit the function of several cell cycle regulators such as the E2F family of transcription factors(28, 33, 35, 36, 43, 44, 45, 46) . The ability of RB protein to arrest the cell cycle depends on sequences necessary for its interaction with E2F(28, 33, 35, 36, 43, 44, 45, 46) . Ectopic overexpression of E2F-1, a member of the E2F-family, can rescue cells from RB-imposed G phase growth arrest, presumably by transactivating E2F-1 target genes that are necessary for entry and progression through the S phase (47, 48, 49) . Moreover, a recent study has identified a carboxyl-terminal region within the A/B pocket domain, designated the C pocket, which binds to the tyrosine kinase, c-Abl(50, 51) . RB can simultaneously bind to c-Abl and E2F; however, in the absence of RB protein, c-Abl does not bind to E2F(51) . In this manner, RB acts a molecular ``matchmaker'' bringing together proteins that would not otherwise interact. Cotransfection studies suggest that coexpression of full-length RB along with an RB deletion mutant designated SE, which contains only the C pocket region(51) , disrupts the ability of RB to suppress growth. The SE mutant binds to, and inhibits the function of, E2F, c-Abl, and perhaps other as yet unknown proteins. Despite inhibition of these protein activities, the SE mutant protects the cells from RB-imposed growth arrest(51) . In other words, RB acts as a growth suppressor only when the A/B and the C pockets are in the cis configuration, suitable for molecular matchmaking, and RB function is inhibited by coexpression of the C pocket domain. Thus, the SE mutant acts as a dominant-negative inhibitor of RB function.

Because IL-1 and TNF- often induce overlapping signal transduction and phenotypic effects, and because IL-1 causes cell cycle arrest in the G/G phase, we sought to examine whether their action is mediated by RB. Data presented here suggest that growth arrest by IL-1 is dependent on RB function, but that by TNF- is mediated by an RB-independent pathway.

MATERIALS AND METHODS

Cell Culture and Cytokines

Plasmid Constructs

DNA Transfections

Assay for [H]Thymidine Incorporation

FACS and Cell Cycle Distribution

Western Blot (Immunoblot) Analysis

RESULTS

IL-1 and TNF- Cause Hypophosphorylation of RB

Figure 1: IL-1 or TNF- cause hypophosphorylation of RB, which correlates with accumulation of cells in G/G phase of the cell cycle. a-c, A375-C6 cells were left untreated (UT) or treated with IL-1 (100 units/ml) or TNF- (100 units/ml) for 24, 48, or 72 h. The cells were harvested, and either whole cell protein extracts were prepared and 20 µg of the indicated extract protein was subjected to Western blot analysis using the anti-RB antibody, C15 (a) or the cells were subjected to FACS analysis, to determine the percentage of cells in the G/G (b) or the S phase (c) at each exposure time. d, phosphorylation status of RB protein. Extracts from cells exposed to IL-1 for 48 h were treated in vitro with vehicle (v) or potato acid phosphatase (PAP) for 15 min and then subjected to Western blot analysis using the anti-RB antibody. These experiments used protein extracts from cells exposed to IL-1 for 72 h as a control for the fast-migrating RB species seen with IL-1 treatment. The slow-migrating differentially phosphorylated forms of RB (pRB) and the fast-migrating unphosphorylated form of RB (RB) are indicated (a and d).

Studies in other cell types have attributed differences in the migration of RB protein in gel electrophoresis to the extent of underphosphorylation of the protein(52) . Since the RB protein is completely dephosphorylated upon treatment with potato acid phosphatase, such a treatment has been used to identify unphosphorylated RB(52) . To help determine whether the slow- and fast-migrating forms of RB represent phosphorylated and differentially underphosphorylated forms, respectively, of RB, we treated the protein extract from A375-C6 cells that had been exposed to IL-1 for 48 h, with vehicle or potato acid phosphatase, and then subjected these extracts to Western blot analysis. Data shown in Fig. 1d indicated that the vehicle-treated extract contained both the slow- and fast-migrating forms of RB (Fig. 1d), similar to those seen after 48-h exposure to IL-1 (compare with Fig. 1a). On the other hand, treatment of the extract with potato acid phosphatase resulted in disappearance of the slow-migrating species and simultaneous appearance of a fast-migrating species (Fig. 1d). This fast-migrating species of RB protein that formed after potato acid phosphatase treatment of the extract comigrated with the fast-migrating species of RB protein that was seen in the extract from cells treated with IL-1 for 72 h (Fig. 1d). These data indicate that the slow-migrating forms of RB represent differentially phosphorylated RB (pRB), whereas the fast-migrating form represents unphosphorylated RB (RB). Similar observations were made when extracts from TNF--treated cells were subjected to potato acid phosphatase (data not shown). These results indicate that IL-1 and TNF- cause a time-dependent hypophosphorylation of RB.

Overexpression of SV40 Large T Antigen Protects Cells from IL-1- or TNF--inducible Growth Inhibition

Figure 2: Overexpression of SV40 large T antigen rescues cells from IL-1- or TNF--inducible growth inhibition. a, transfectant cells express T antigen or K1 mutant. A375-C6 cells were transfected with pSG5-SV40 large T antigen plasmid encoding the SV40 large T antigen, or pSG5-K1 plasmid encoding the K1 mutant of T antigen, and stable transfectant cell lines were selected. Protein extracts from cell lines C6/T.L1 or C6/K1.L1 transfected with constructs encoding the T antigen or the K1 mutant, respectively or parent A375-C6 cells (C6) for a control were subjected to Western blot analysis using an anti-T antigen antibody. The bands corresponding to the large T antigen and K1 mutant are indicated. b, transfectant cells expressing T antigen do not show increased hypophosphorylation of RB in response to IL-1 or TNF-. The transfectant cells were left untreated (UT) or treated with IL-1 or TNF- for 48 or 72 h as indicated, and whole cell protein extracts were examined by Western blot analysis for RB expression. As a control for the unphosphorylated form of RB, we used a protein extract (50 µg of protein) from A375-C6 cells (C6) which were exposed to IL-1 for 72 h (right panel). The differentially phosphorylated (pRB) and unphosphorylated (RB) forms of RB are shown. C6/T.L1 cells (right panel), which were left untreated or treated with IL-1 or TNF-, expressed primarily pRB, whereas K1.L1 cells (left panel) showed hypophosphorylation of RB protein upon exposure to IL-1 or TNF-. c, overexpression of T antigen abrogates the growth arrest response to IL-1 or TNF-. The transfectant cell lines were left unexposed or exposed to IL-1 or TNF- for 48 or 72 h, and the effect on growth was examined by [H]thymidine incorporation studies. Percent growth inhibition is expressed as a function of cytokine exposure time.

To address whether ectopic overexpression of the T antigen or K1 mutant affected the RB phosphorylation status in response to IL-1 or TNF-, the transfectant cell lines, confirmed to express the large T antigen or the K1 mutant, were left unexposed or exposed to IL-1 or TNF- for 48 or 72 h, and whole cell protein extracts were examined by Western blot analysis for RB expression. Because the extracts from the SV40 T antigen transfected cells were resolved on a separate gel, we used protein extract from nontransfected A375-C6 cells exposed to IL-1 for 72 h, as a control for the fast-migrating unphosphorylated form of RB (Fig. 2b, right panel). As seen in Fig. 2b (right panel), the control extract from A375-C6 cells exposed to IL-1 for 72 h primarily showed the fast-migrating unphosphorylated form of RB. On the other hand, C6/T.L1 transfectant cells, primarily expressed the phosphorylated form of RB protein whether or not they were exposed to IL-1 or TNF- for 72 h (Fig. 2b, right panel). By contrast, C6/K1.L1 transfectant cells showed hypophosphorylation of RB upon exposure to IL-1 or TNF- for 48 or 72 h (Fig. 2b, left panel). Each of three different transfectant lines expressing the T antigen or K1 mutant were examined in this manner by Western blot analysis for RB phosphorylation status, and the results (not shown) were similar to those presented in Fig. 2b. These studies indicated that the SV40 large T antigen inhibited the ability of IL-1 or TNF- to evoke hypophosphorylation of RB.

Because the large T antigen preferentially binds and sequesters RB(35, 52) , and overexpression of T antigen resulted in lack of RB accumulation in response to IL-1 (Fig. 2b), we reasoned that if RB was involved in IL-1-inducible growth inhibition, overexpression of the T antigen would protect the cells from IL-1 action. To test this hypothesis, the transfectant cell lines that expressed the large T antigen or K1 mutant were left unexposed or exposed to IL-1 or TNF- for 48 or 72 h, and the effect on growth was examined by [H]thymidine incorporation studies. The transfectant cell line, C6/K1.L1, which expressed the K1 mutant, showed a time-dependent growth arrest response to the cytokines: in response to IL-1, the cells showed about 50 and 80% growth inhibition in 48 and 72 h, respectively; and in response to TNF-, these cells showed about 45% and 80% growth inhibition in 48 and 72 h, respectively (Fig. 2c). The extent of growth inhibition resulting from exposure of C6/K1.L1 cells to IL-1 or TNF- for 48 or 72 h was similar to that seen in parent A375-C6 cells exposed to IL-1 or TNF- for the corresponding time periods (data not shown and (8) ). On the other hand, the transfectant cell line, C6/T.L1, which expressed the SV40 large T antigen, was relatively resistant to IL-1, i.e. about 20 and 35% growth inhibition was seen in 48 and 72 h, respectively, and to TNF-, i.e. about 20 and 30% growth inhibition was seen in 48 and 72 h, respectively (Fig. 2c). These data suggest that the SV40 large T antigen can rescue the cells from the growth arresting actions of IL-1 and TNF-.

Dominant-negative Mutants of Rb Rescue A375-C6 Cells from IL-1- and TNF--inducible Growth Arrest

Figure 3: SE protects A375-C6 cells from IL-1-inducible growth arrest. a, transfectant cells express Rb-deletion plasmids. A375-C6 cells were transfected with plasmids encoding SE, SE, or ME, and G418 sulfate-resistant transfectant cell lines were selected. Whole cell protein extracts were prepared from parent A375-C6 cells (C6) or the transfectant cell lines SE.L1 (C6/SE), SE.L1 (C6/SE), and ME.L1 (C6/ME) and subjected to Western blot analysis using the anti-RB antibody, C15. Arrows indicate position of SE or SE (upper arrow; 18 kDa) and ME (lower arrow; 12 kDa) proteins. b and c, SE or SE abrogates IL-1-inducible growth arrest. The transfectant cell lines, SE.L1, SE.L1 or ME.L1, were left unexposed or exposed to TNF- (b) or IL-1 (c) for 48 or 72 h, and the effect on growth was examined by [H]thymidine incorporation studies. Percent growth inhibition in the transfectant cell lines is expressed as a function of cytokine exposure time. d, IL-1 causes hypophosphorylation of RB in SE transfectant cells. SE.L1 cells were left untreated (UT) or treated with IL-1 for 48 or 72 h, and whole cell protein extracts were subjected to Western blot analysis for RB protein. The phosphorylated (pRB) and unphosphorylated RB (RB) forms are shown.

To determine whether ectopic expression of SE, SE, or ME could rescue the cells from growth arrest by IL-1 or TNF-, the transfectant cell lines, SE.L1, SE.L1, or ME.L1, were left unexposed or exposed to IL-1 or TNF- for various intervals of time, and the effect on growth was examined by [H]thymidine incorporation studies. ME.L1 cells showed growth inhibition in response to IL-1 and TNF- with kinetics similar to those seen in parent A375-C6 cells (Fig. 3, b and c). Similarly, the growth of SE.L1 and SE.L1 transfectant cells was inhibited by TNF- (Fig. 3b). By contrast, SE.L1 and SE.L1 transfectant cells were relatively resistant to the growth arresting action of IL-1: a maximum of about 25-35% growth arrest was seen in 48 or 72 h (Fig. 3c). Three different transfectant cell lines for SE, SE, and ME were examined for expression of the Rb derivatives and susceptibility to IL-1 or TNF-, and the observations (data not shown) were similar to those described for Fig. 3, a-c. These results suggest that the dominant-negative mutants of RB, SE, and SE, protect cells from IL-1 but not from TNF- action. Thus, RB plays a role in the growth-arresting action of IL-1, but may be a dispensable component of the TNF--inducible growth arrest pathway. The accumulation of hypophosphorylated RB upon exposure to TNF-, therefore, seems to be a consequence of G/G phase growth arrest mediated by another checkpoint control protein. Further studies will examine whether the RB-related proteins, p107 or p130, mediate the action of TNF- in these cells.

To determine whether ectopic expression of SE, which protected the cells from IL-1- but not TNF--inducible growth inhibition, affected the phosphorylation status of RB in response to the cytokines, SE.L1 cells were left unexposed or exposed to IL-1 for 48 or 72 h, and whole cell protein extracts were examined by Western blot analysis for RB expression. As seen in Fig. 3d, IL-1 caused a time-dependent hypophosphorylation of RB in the SE.L1 cells, in a manner similar to that seen in the parent cells (compare with Fig. 1). Since IL-1-inducible growth arrest was abrogated in SE.L1 cells, these results suggest that SE provides protection from IL-1 action without interfering with the ability of the cytokine to cause hypophosphorylation of RB.

Ectopic E2F-1 Expression Rescues Cells from IL-1- and TNF--inducible Growth Arrest

Figure 4: Ectopic expression of E2F-1 rescues A375-C6 cells from IL-1 action. a, transfectant cells express full-length E2F-1 or E2F-1(1-368) deletion protein. A375-C6 cells were left nontransfected or were transfected with the full-length E2F.1 expression construct or the transactivation-deficient deletion construct E2F-1(1-368), and stable transfectant cell lines E2F-1.L1 and E2F-1(1-368).L1 were selected. Protein extracts were prepared from parent A375-C6 cells (C6) or the transfectant cell lines C6/E2F-1.L1 and C6/E2F-1(1-368).L1 and subjected to Western blot analysis, using anti-E2F-1 antibody. Arrows indicate position of E2F-1 (upper thick arrow) and E2F-1(1-368) mutant (lower thin arrow). The right and left panels represent different immunoblots. b and c, overexpression of E2F-1 abrogates IL-1- or TNF--inducible growth inhibition. Transfectant cells, E2F-1.L1 and E2F-1(1-368).L1, were exposed to IL-1 or TNF- for 24, 48, or 72 h and then subjected to [H]thymidine incorporation assays. Percent growth inhibition is expressed as a function of IL-1 or TNF- exposure time.

We then exposed the transfectant cells to IL-1 or TNF- for 24, 48 or 72 h and performed [H]thymidine incorporation experiments, to determine their susceptibility to the cytokines. The E2F-1 transfectant cell line, E2F-1.L1, showed 5, 10, or 30% growth inhibition in response to IL-1 in 24, 48, or 72 h, respectively (Fig. 4b), and <5, 15, or 35% growth inhibition in response to TNF- in 24, 48, or 72 h, respectively (Fig. 4c). On the other hand, the E2F-1(1-368) transfectant cell line E2F-1(1-368).L1 showed about 20, 50, or 80% growth inhibition in response to the cytokines in 24, 48, or 72 h, respectively (Fig. 4, b and c). Three different transfectant cell lines for E2F-1 or E2F-1(1-368) were examined in this manner and the results (not shown) were similar to those described above in Fig. 4, a-c. These data suggest that ectopic expression of E2F-1 can rescue the melanoma cells from growth arrest by IL-1 and are consistent with the view that RB plays a role in IL-1 action. However, the rescue of cells expressing E2F-1 from the growth arresting action of TNF- is particularly interesting, because the data in Fig. 3suggest that the action of this cytokine is not mediated via RB hypophosphorylation. It is possible, therefore, that the action of TNF- is mediated by an RB-related protein, perhaps p107, p130, or another checkpoint control protein whose expression or function may be modulated or circumvented by expression of E2F-1. As the transactivation-deficient mutant of E2F-1 did not rescue the cells from IL-1 or TNF- action, the data imply that the transactivation function of ectopically expressed E2F-1 is required for protection from IL-1-evoked hypophosphorylation of RB or TNF--mediated growth arrest via an RB-related protein.

DISCUSSION

The present study revealed that in melanoma cells, A375-C6, IL-1, or TNF-, invoke hypophosphorylation of RB, and the extent of hypophosphorylation correlates with inhibition of growth and accumulation of cells in the G/G phase of the cell cycle. Since un(der)phosphorylated RB has been implicated in the G/G phase growth arrest caused by another cytokine, transforming growth factor-(52, 53) , we sought to determine whether RB was functionally involved in the action of IL-1 or TNF-. We began by asking whether the SV40 large T antigen, which has been shown to preferentially overcome the growth suppressor action of hypophosphorylated RB, could abrogate the growth arresting action of the cytokines. Previous studies (52, 53) evaluating the role of hypophosphorylated RB in TGF--inducible G/G growth arrest in other cell types have shown that the SV40 large T antigen can rescue the cells from the G/G block. The rescue action of the large T antigen is attributed to its ability to displace the key proteins, particularly those of the E2F family, that are sequestered in the A/B pocket domain by hypophosphorylated RB, to sequester hypophosphorylated RB, and to trigger the phosphorylation of RB(35, 52) . Our studies in the melanoma cells indicated that the large T antigen, but not the K1 mutant, which cannot bind to RB, could rescue the cells from the action of IL-1 or TNF-. This observation suggested that hypophosphorylated RB, a target of the large T antigen, was likely to be involved in the action of these cytokines. However, because the large T antigen is known to bind to other key G/G checkpoint control proteins, such as the RB-related proteins p107 and p130, the experiments with the large T antigen did not conclusively identify RB as a functional mediator of either IL-1 or TNF- action. To definitively identify RB as a mediator of IL-1- or TNF--inducible growth arrest, we used dominant-negative mutants of RB. The SE mutant selectively inhibits the function of RB, but not of the other key G/G checkpoint control proteins, by interfering with the ability of RB to act as a molecular matchmaker and assemble protein complexes(51) . Ectopic expression of SE abrogated the ability of IL-1, but not of TNF-, to cause growth arrest in the melanoma cells, implying that RB is an important mediator of IL-1-inducible growth arrest. However, because growth arrest by IL-1 was not completely blocked by SE, we cannot exclude the possibility that other checkpoint control proteins are also involved in IL-1 action. By contrast, IL-1 causes growth stimulation in human fibroblast cells, WI-38, or human glioblastoma cells, U373-MG, and does not invoke hypophosphorylation of RB. ()The cell surface receptor, IL-1-receptor type I, is involved in both the growth inhibitory and growth stimulatory actions of IL-1 in different cell lines(22, 23, 24) . The induction of RB hypophosphorylation in the melanoma cells, but not in the fibroblasts or glioblastoma cells, suggests that cell type-specific differences characterized by the signaling components that are located downstream of the receptor and that lead to the differential regulation of RB phosphorylation are responsible for the pleiotrophic growth effects of IL-1. Further studies directed toward identifying the individual components of the signaling pathway responsible for hypophosphorylation of RB will help delineate the molecular basis of the pleiotrophic growth effects of IL-1.

The mechanism(s) by which RB mediates growth arrest is an area of intense investigation. The dominant-negative mutants of RB disrupt the capacity of RB to form protein complexes, but they do not alter the hypophosphorylation status of RB ((51) ; this study), nor do they restore E2F transactivation function in transfectant cells(51) , suggesting that rescue from hypophosphorylated RB-mediated growth inhibition can occur in the absence of functional E2F. Nevertheless, ectopic overexpression of one of the RB-target proteins, E2F-1, provides protection from the growth inhibitory action of hypophosphorylated RB ((46) ; this study). It is obvious, therefore, that the dominant-negative mutants of RB and ectopically overexpressed E2F-1 use different mechanisms to overcome the effect of hypophosphorylated RB. This hypothesis is being tested so as to elucidate the mechanism(s) by which IL-1-inducible accumulation of hypophosphorylated RB causes growth inhibition.

Although the biological actions of IL-1 and TNF- are initiated by the binding of the cytokines to distinct cell surface receptors (22, 23, 24, 25) , these cytokines generally show overlapping biological activities and the induction of similar immediate-early gene programs (13) . However, by using the dominant-negative mutants of RB, the present study has revealed that the G/G growth arresting action of IL-1 is dependent on the hypophosphorylation of the RB protein, but the action of TNF- is independent of RB hypophosphorylation. Because E2F-1 overexpression rescues the cells from the action of TNF-, an RB-related protein like p107 or p130 may possibly mediate the action of this cytokine. The ability of the dominant-negative mutants of RB to selectively overcome the action of IL-1, and not that of TNF-, indicates the usefulness of these mutants in dissecting the growth inhibitory pathways regulated by RB and other related checkpoint control proteins.

FOOTNOTES

*

This work was supported by United States Public Health Service-National Institutes of Health Grant CA52837, a McDowell Cancer Foundation Grant, and by Division of Urology Research Funds (to V. M. R.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§

To whom correspondence should be addressed: Combs Research Bldg., Rm. 303, 800 Rose St., Lexington, KY 40536. Tel.: 606-257-2677; Fax: 606-257-8940.

()

The abbreviations used are: IL-1, interleukin-1; TNF-, tumor necrosis factor-; FACS, fluorescence-assisted cell sorting.

()

S. Muthukkumar and V. M. Rangnekar, unpublished data.

ACKNOWLEDGEMENTS

REFERENCES

1. Dinarello, C. A. (1991) Blood 77, 1627-1652 [Abstract/Free Full Text]
2. Giovine, F. S. D., and Duff, G. W. (1990) Immunol. Today 11, 13-20 [CrossRef][Medline] [Order article via Infotrieve]
3. Beutler, B., and Cerami, A. (1988) Annu. Rev. Biochem. 57, 505-518 [CrossRef][Medline] [Order article via Infotrieve]
4. Fiers, W. (1991) FEBS Lett. 285, 199-215 [CrossRef][Medline] [Order article via Infotrieve]
5. Aggarwal, B. B., and Vilcek, J. (eds) (1992) Marcel Dekker, New York
6. Schmidt, J. A., Mizel, S. B., Cohen, D., and Green, I. (1982) J. Immunol. 128, 2177-2182 [Medline] [Order article via Infotrieve]
7. Vilcek, J., Palombella, V. J., Henriksen-Destefano, D., Swenson, C., Feinman, R., Hirai, M., and Tsujimoto, M. (1986) J. Exp. Med. 163, 632-643 [Abstract/Free Full Text]
8. Rangnekar, V. V., Waheed, S., Davies, T. J., Toback, F. G., and Rangnekar, V. M. (1991) J. Biol. Chem. 266, 2415-2422 [Abstract/Free Full Text]
9. Endo, Y., Matsushima, K., Onozaki, K., and Oppenheim, J. J. (1988) J. Immunol. 141, 2342-2348 [Abstract]
10. Lachman, L. B., Brown, D. C., and Dinarello, C. A. (1987) J. Immunol. 138, 2913-2916 [Abstract]
11. Koch, I., Depenbrock, H., Danhauser-Riedl, S., Rastetter, J. W., and Hanauske, A. R. (1995) Br. J. Cancer 71, 794-800 [Medline] [Order article via Infotrieve]
12. Belizario, J. E., and Dinarello, C. A. (1991) Cancer Res. 51, 2379-2385 [Abstract/Free Full Text]
13. Rangnekar, V. V., Waheed, S., and Rangnekar, V. M. (1992) J. Biol. Chem. 267, 6240-6248 [Abstract/Free Full Text]
14. Danforth, D. N., and Sgagias, M. K. (1991) Cancer Res. 51, 1488-1493 [Abstract/Free Full Text]
15. Fryling, C., Dombalagian, M., Burgess, W., Hollander, N., Schrieber, A. B., and Haimovich, J. (1989) Cancer Res. 49, 3333-3337 [Abstract/Free Full Text]
16. Kilian, P. L., Kaffka, K. L., Biondi, D. A., Lipman, J. M., Benjamin, W. R., Feldman, D., and Campen, C. A. (1991) Cancer Res. 51, 1823-1828 [Abstract/Free Full Text]
17. Onozaki, K., Urawa, H., Tamatani, T., Iwamura, Y., Hashimoto, T., Baba, T., Suzuki, H., Yamada, M., Yamamoto, S., Oppenheim, J. J., and Matsushima, K. (1988) J. Immunol. 140, 112-119 [Abstract]
18. Lord, K. A., Abdollahi, A., Hoffman-Liebermann, B., and Liebermann, D. A. (1990) Cell Growth & Differ. 1, 637-645
19. Sims, J. E., March, C. J., Cosman, D., Widmer, M. B., MacDonald, H. R., McMahan, C. J., Grubin, C. E., Wignall, J. M., Jackson, J. L., Call, S. M., Friend, D., Alpert, A. R., Gillis, S., Urdal, D. L., and Dower, S. K. (1988) Science 241, 585-589 [Abstract/Free Full Text]
20. McMahan, C. J., Slack, J. L., Mosley, B., Cosman, D., Lupton, S. D., Brunton, L. L., Grubin, C. E., Wignall, J. M., Jenkins, N. A., Brannan, C. I., Copeland, N. G., Huebner, K., Croce, C. M., Cannizzarro, L. A., Benjamin, D., Dower, S. K., Spriggs, M. K., and Sims, J. E. (1991) EMBO J. 10, 2821-2832 [Medline] [Order article via Infotrieve]
21. Tartaglia, L. A., and Goeddel, D. V. (1992) Immunol. Today 13, 151-153 [CrossRef][Medline] [Order article via Infotrieve]
22. Colotta, F., Re, F., Muzio, M., Bertini, R., Polentarutti, N., Sironi, M., Giri, J. G., Dower, S. K., Sims, J. E., and Mantovani, A. (1993) Science 261, 472-475 [Abstract/Free Full Text]
23. Sims, J. E., Gayle, M. A., Slack, J. L., Alderson, M. R., Bird, T. A., Giri, J. G., Colotta, F., Re, F., Mantovani, A., and Shanebeck, K. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6155-6159 [Abstract/Free Full Text]
24. Sells, S. F., Muthukkumar, S., Sukhatme, V. P., Crist, S. C., and Rangnekar, V. M. (1995) Mol. Cell. Biol. 15, 682-692 [Abstract]
25. Tartaglia, L. A., Weber, R. F., Figari, I. S., Reynolds, C., Palladino, M. A., and Goeddel, D. V. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 9292-9296 [Abstract/Free Full Text]
26. Joshi-Barve, S. S., Rangnekar, V. V., Sells, S. F., and Rangnekar, V. M. (1993) J. Biol. Chem. 268, 18018-18029 [Abstract/Free Full Text]
27. Sluss, H. K., Barrett, T., Derijard, B., and Davis, R. J. (1994) Mol. Cell. Biol. 14, 8376-8384 [Abstract/Free Full Text]
28. DeCaprio, J. A., Ludlow, J. W., Lynch, D., Furukawa, Y., Griffin, J., Piwnica-Worms, H., Huang, C.-M., and Livingston, D. M. (1989) Cell 58, 1085-1095 [CrossRef][Medline] [Order article via Infotrieve]
29. Wang, J. Y. J., Knudsen, E. S., and Welch, P. J. (1994) Adv. Cancer Res. 64, 25-85 [Medline] [Order article via Infotrieve]
30. Bookstein, R., and Lee, W.-H. (1991) CRC Crit. Rev. Oncogenesis 2, 211-227
31. Huang, H.-J. S., Yee, J.-K., Shew, J.-Y., Chen, P.-L., Bookstein, R., Friedmann, T., Lee, E. Y.-H., and Lee, W.-H. (1988) Science 242, 1563-1566 [Abstract/Free Full Text]
32. Fung, Y.-K. T., T'Ang, A., Murphree, L., Zhang, F.-H., Qiu, W.-R., Wang, S.-W., Shi, X.-H., Lee, L., Driscoll, B., and Wu, K.-J. (1993) Oncogene 8, 2659-2672 [Medline] [Order article via Infotrieve]
33. Hu, Q., Dyson, N., and Harlow, E. (1990) EMBO J. 9, 1147-1155 [Medline] [Order article via Infotrieve]
34. Huang, S., Wang, N. P., Tseng, B. Y., Lee, W.-H., and Lee, E. Y.-H. (1990) EMBO J. 9, 1815-1822 [Medline] [Order article via Infotrieve]
35. Kaelin, W. G., Ewen, M. E., and Livingston, D. M. (1990) Mol. Cell. Biol. 10, 3761-3769 [Abstract/Free Full Text]
36. Nevins, J. R. (1992) Science 258, 424-429 [Abstract/Free Full Text]
37. Buchkovich, K., Duffy, L. A., and Harlow, E. (1989) Cell 58, 1097-1105 [CrossRef][Medline] [Order article via Infotrieve]
38. Chen, P., Scully, P., Shew, J., Wang, J. Y., and Lee, W. (1989) Cell 58, 1193-1198 [CrossRef][Medline] [Order article via Infotrieve]
39. DeCaprio, J. A., Furukawa, Y., Ajchenbaum, F., Griffin, J. D., and Livingston, D. M. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 1795-1798 [Abstract/Free Full Text]
40. Ludlow, J. W., Glendening, C. L., Livingston, D. M., and DeCaprio, J. A. (1993) Mol. Cell. Biol. 13, 367-372 [Abstract/Free Full Text]
41. Mihara, K., Cao, X., Yen, A., Chandler, S., Driscoll, B., Murphree, A. L., T'Ang, A., and Fung, Y. (1989) Science 246, 1300-1303 [Abstract/Free Full Text]
42. Ludlow, J. W., DeCaprio, J. A., Huang, C., Lee, W., Paucha, E., and Livingston, D. M. (1989) Cell 56, 57-65 [CrossRef][Medline] [Order article via Infotrieve]
43. Hiebert, S. W., Chellappan, S. P., Horowitz, J. M., and Nevins, J. R. (1992) Genes & Dev. 6, 177-185
44. Hiebert, S. W., Blake, M., Azizkhan, J., and Nevins, J. R. (1993) Mol. Cell. Biol. 13, 3384-3391 [Abstract/Free Full Text]
45. Qian, Y., Luckey, C., Horton, L., Esser, M., and Templeton, D. J. (1992) Mol. Cell. Biol. 12, 5363-5372 [Abstract/Free Full Text]
46. Qin, X.-Q., Livingston, D. M., Ewen, M., Sellers, W. R., Arany, Z., and Kaelin, W. G., Jr. (1995) Mol. Cell. Biol. 15, 742-755 [Abstract]
47. Blake, M. C., and Azizkhan, J. C. (1989) Mol. Cell. Biol. 9, 4994-5002 [Abstract/Free Full Text]
48. Slansky, J. E., Li, Y., Kaelin, W. G., and Farnham, P. J. (1993) Mol. Cell. Biol. 13, 1610-1618 [Abstract/Free Full Text]
49. Farnham, P. J., Slansky, J. E., and Kollmar, R. (1993) Biochim. Biophys. Acta 1155, 125-131 [Medline] [Order article via Infotrieve]
50. Welch, P. J., and Wang, J. Y. J. (1993) Cell 75, 779-790 [CrossRef][Medline] [Order article via Infotrieve]
51. Welch, P. J., and Wang, J. Y. J. (1995) Genes & Dev. 9, 31-46
52. Laiho, M., DeCaprio, J. A., Ludlow, J. W., Livingston, D. M., and Massague, J. (1990) Cell 62, 175-185 [CrossRef][Medline] [Order article via Infotrieve]
53. Landesman, Y., Pagano, M., Draetta, G., Rotter, V., Fusenig, N. E., and Kimchi, A. (1992) Oncogene 7, 1661-1665 [Medline] [Order article via Infotrieve]

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				L. Ying, A. B. Hofseth, D. D. Browning, M. Nagarkatti, P. S. Nagarkatti, and L. J. Hofseth Nitric Oxide Inactivates the Retinoblastoma Pathway in Chronic Inflammation Cancer Res., October 1, 2007; 67(19): 9286 - 9293. [Abstract] [Full Text] [PDF]

				L.-C. Wang, C. Y. Okitsu, and E. Zandi Tumor Necrosis Factor {alpha}-dependent Drug Resistance to Purine and Pyrimidine Analogues in Human Colon Tumor Cells Mediated through IKK J. Biol. Chem., March 4, 2005; 280(9): 7634 - 7644. [Abstract] [Full Text] [PDF]

				J. Bai, H. Nakamura, S. Ueda, Y.-W. Kwon, T. Tanaka, S. Ban, and J. Yodoi Proteasome-dependent Degradation of Cyclin D1 in 1-Methyl-4-phenylpyridinium Ion (MPP+)-induced Cell Cycle Arrest J. Biol. Chem., September 10, 2004; 279(37): 38710 - 38714. [Abstract] [Full Text] [PDF]

				A. Nalca and V. M. Rangnekar The G1-phase Growth-arresting Action of Interleukin-1 Is Independent of p53 and p21/WAF1 Function J. Biol. Chem., November 13, 1998; 273(46): 30517 - 30523. [Abstract] [Full Text] [PDF]

				M. R. Bennett, K. Macdonald, S.-W. Chan, J. J. Boyle, and P. L. Weissberg Cooperative Interactions Between RB and p53 Regulate Cell Proliferation, Cell Senescence, and Apoptosis in Human Vascular Smooth Muscle Cells From Atherosclerotic Plaques Circ. Res., April 6, 1998; 82(6): 704 - 712. [Abstract] [Full Text] [PDF]

				J. N. Lavoie, G. L'Allemain, A. Brunet, R. Muller, and J. Pouyssegur Cyclin D1 Expression Is Regulated Positively by the p42/p44MAPK and Negatively by the p38/HOGMAPK Pathway J. Biol. Chem., August 23, 1996; 271(34): 20608 - 20616. [Abstract] [Full Text] [PDF]

				T. Murai, Y. Nakagawa, H. Maeda, and K. Terada Altered Regulation of Cell Cycle Machinery Involved in Interleukin-1-induced G1 and G2 Phase Growth Arrest of A375S2 Human Melanoma Cells J. Biol. Chem., February 23, 2001; 276(9): 6797 - 6806. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Muthukkumar, S. Articles by Rangnekar, V. M. Search for Related Content PubMed PubMed Citation Articles by Muthukkumar, S. Articles by Rangnekar, V. M. Social Bookmarking                      What's this?